In a study published in the American Journal of Gastroenterology, researchers discovered significantly greater angiotensin-converting enzyme 2 (ACE2) expression and messenger RNA (mRNA) expression in the upper gastrointestinal (GI) tracts of proton pump inhibitor (PPI) users, which may predispose them to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. PPI use at admission was linked to heightened in-hospital mortality in patients with coronavirus disease 2019 (COVID-19), particularly African Americans. Most patients were taking PPIs for discretionary indications such as nonsteroidal anti-inflammatory drug (NSAID) prophylaxis and symptoms of gastroesophageal reflux disease (GERD).
The researchers conducted a prospective study of hospitalized COVID-19 patients and COVID-negative controls to understand how PPI use may affect ACE2 expression and stool SARS-CoV-2 RNA. A retrospective cohort of hospitalized patients (from six hospitals) with COVID-19 from March 15, 2020, to August 15, 2020, was assessed to explore the association between PPI use and mortality. Covariates with clinical relevance to COVID-19 outcomes were included in order to determine predictors of in-hospital mortality.
Salivary ACE2 mRNA levels were greater in control PPI users compared with nonusers (2.39 vs. 1.22; P = .02). PPI users and nonusers had similar salivary ACE2 levels and stool SARS-CoV-2 RNA detection rates. The authors noted, "In 694 hospitalized patients with COVID-19 (age = 58 years, 46% men, and 65% African American), mortality rate in PPI users and nonusers was 30% (68/227) vs. 12.1% (53/439), respectively."
According to the researchers, PPI use (adjusted odds ratio [aOR] = 2.72, P <.001); age (aOR = 1.66 per decade, P <.001); race (aOR = 3.03, P = .002); cancer (aOR = 2.22, P = .008); and diabetes (aOR = 1.95, P = .003) were predictors of mortality by logistic regression. African American patients had a greater PPI-correlated mortality risk (aOR = 4.16, 95% CI: 2.28-7.59) compared with other patients (aOR = 1.62, 95% CI: 0.82-3.19, P = .04 for interaction).
Lead author and study investigator Julia J. Liu, MD, MSc, and colleagues, wrote, "We found significantly higher [angiotensin-converting enzyme 2 (ACE2)] messenger RNA expression levels in upper [gastrointestinal] tract of PPI users, which may predispose them to SARS-CoV-2 infection. The association of the higher ACE2 expression in PPI users with respect to outcomes was assessed in our retrospective cohort of hospitalized patients with COVID-19, which included our prospective research participants: PPI usage at admission was associated with increased mortality."
"This mortality risk was particularly profound in African American patients with adjusted OR of 4.16, a finding that has not been previously reported. In fact, the majority (59%) of COVID-19 deaths in [African Americans] were in PPI users. Remarkably, most patients with COVID-19 (87%) were taking PPIs for discretionary indications, such as nonerosive [gastroesophageal reflux disease (GERD)] and/or NSAID ulcer prophylaxis. The increased ACE2 expression of the GI tract of COVID-negative patients on PPI provides a potential mechanistic basis for the increased SARS-CoV-2 infection and worse outcomes observed in PPI users during the pandemic reported in previous studies."
The content contained in this article is for informational purposes only. The content is not intended to be a substitute for professional advice. Reliance on any information provided in this article is solely at your own risk.
« Click here to return to Gastro Update.
Published September 23, 2021